SOL-116
Rheumatoid Arthritis (RA)
About Lipum
Lipum is a clinical-phase biotech company developing first-in-class biologic therapies for chronic inflammatory diseases. Its lead asset, SOL-116, is a humanized antibody targeting the novel BSSL pathway and has completed a Phase 1 trial, supporting further development for rheumatoid arthritis. The company recently completed a merger with Flerie in March 2026, operates with a lean, virtual R&D model utilizing external partners, and has secured significant EU grant funding.
View full company profileAbout Lipum
Lipum is a clinical-phase biotech company developing first-in-class biologic therapies for chronic inflammatory diseases. Its lead asset, SOL-116, is a humanized antibody targeting the novel BSSL pathway and has completed a Phase 1 trial, supporting further development for rheumatoid arthritis. The company recently completed a merger with Flerie in March 2026, operates with a lean, virtual R&D model utilizing external partners, and has secured significant EU grant funding.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis (RA) Drugs
| Drug | Company | Phase |
|---|---|---|
| ABO21009 | AboleIIs Pharma | Phase 1 |
| GlyHealth Biomarkers | Avenna | Pre-clinical/Validation |
| MYMD-1® | TNF Pharmaceuticals | Phase 2 |
| Telitacicept | Vor Biopharma | Marketed |